Wound Management Technologies Inc  

(Public, OTCMKTS:WNDM)   Watch this stock  
Find more results for PINK:WNDM
+0.0012 (2.00%)
Mar 26 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.06 - 0.06
52 week 0.03 - 0.12
Open 0.06
Vol / Avg. 176,900.00/50,810.00
Mkt cap 5.44M
P/E     -
Div/yield     -
EPS -0.04
Shares 88.90M
Beta 57.97
Inst. own 0%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -98.81% -240.28%
Operating margin -95.34% -173.19%
EBITD margin - -166.63%
Return on average assets -129.22% -349.94%
Return on average equity - -
Employees 4 -
CDP Score - -


Suite 3100 777 Main Street
United States - Map
+1-817-8207080 (Phone)

Website links


Wound Management Technologies, Inc. is engaged in developing and marketing products for the advanced wound care market, as pursued through the Company�s wholly owned subsidiary, Wound Care Innovations, LLC (WCI), which brings a mix of products, procedures and expertise to the wound care arena and surgical wounds. The Company�s CellerateRX is cleared by the Food and Drug Administration (FDA) as a medical device for use on all acute and chronic wounds, except third degree burns, and is ready for distribution in both gel and powder form. CellerateRX is available without a prescription and the wound care products are approved for reimbursement under Medicare Part B. CellerateRX wound care and surgical products are sold through independent distributors, distributor organizations, healthcare distributors, representatives and through inside sales activities.

Officers and directors

Robert H. Lutz Jr. Chairman of the Board, Chief Executive Officer
Age: 64
Deborah Jenkins Hutchinson President, Director
Age: 55
Darren Stine Chief Financial Officer
Age: 43
John Feltman Director
Age: 65
Ronald L. Goode Ph.D. Director
Age: 70
John Siedhoff Director
Araldo A. Cossutta Independent Director
Age: 88
Robert E. Gross Independent Director
Age: 68